Uploaded July 2025 | Updated September 2026, 2 weeks ago
FDA Approval & Phase III Aranote Trial Information: fda.gov/drugs/resources-information-approved-drugs/fda-approves-darolutamide-metastatic-castration-sensitive-prostate-cancer
Donate to PCRI: pcri.org/donate
For more information, visit pcri.org
1:04 What is Nubeqa and how does it work?
2:24 Does taking more intense therapy earlier on accelerate side effects?
4:43 Does adding Nubeqa to Orgovyx negate the latter’s quick recovery time?
5:34 Are there any Nubeqa-specific side effects or tests?
6:22 Do patient usually take 600 mg of oral Nubeqa twice daily?
6:53 Should those with low-volume disease take Nubeqa?
9:33 Will Nubeqa be implemented earlier in treatment in the future?
10:52 Alex’s conclusions
Don't know your stage? Take the quiz: visit prostatecancerstaging.org
To learn more about prostate cancer, visit pcri.org
Sign up for our newsletter here to receive the latest updates on prostate cancer and the PCRI: pcri.org/join
Who we are:
The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better-individualized care. Feel free to explore our website at pcri.org or contact our free helpline with any questions that you have at pcri.org/helpline. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.
FDA Approval & Phase III Aranote Trial Information: fda.gov/drugs/resources-information-approved-drugs/fda-approves-darolutamide-metastatic-castration-sensitive-prostate-cancer
Donate to PCRI: pcri.org/donate
For more information, visit pcri.org
1:04 What is Nubeqa and how does it work?
2:24 Does taking more intense therapy earlier on accelerate side effects?
4:43 Does adding Nubeqa to Orgovyx negate the latter’s quick recovery time?
5:34 Are there any Nubeqa-specific side effects or tests?
6:22 Do patient usually take 600 mg of oral Nubeqa twice daily?
6:53 Should those with low-volume disease take Nubeqa?
9:33 Will Nubeqa be implemented earlier in treatment in the future?
10:52 Alex’s conclusions
Don't know your stage? Take the quiz: visit prostatecancerstaging.org
To learn more about prostate cancer, visit pcri.org
Sign up for our newsletter here to receive the latest updates on prostate cancer and the PCRI: pcri.org/join
Who we are:
The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better-individualized care. Feel free to explore our website at pcri.org or contact our free helpline with any questions that you have at pcri.org/helpline. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.
